AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced today the initiation of the Phase 3 IAP312 study of Zalviso, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE